Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenhoff, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenhoff, S
Haematologica, Vol 91, Issue 9, 1228-1233
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation

S Lenhoff, M Hjorth, I Turesson, J Westin, P Gimsing, F Wisloff, L Ahlberg, K Carlson, I Christiansen, IM Dahl, K Forsberg, L Brinch, J Hammerstrom, HE Johnsen, LM Knudsen, O Linder, UH Mellqvist, I Nesthus, JL Nielsen, and

Department of Hematology, University Hospital, S-221 85 Lund, Sweden. Stig.Lenhoff@skane.se

BACKGROUND AND OBJECTIVES: From 1994 to 1997 we conducted a population-based, prospective study on intensive therapy in newly diagnosed symptomatic myeloma patients younger than 60 years, comparing their survival to that of a conventionally treated historic population. Long-term results are presented, including the impact of the degree of response on survival and relapse pattern after transplantation. DESIGN AND METHODS: The prospective population was formed of 397 patients and the historic population of 313 patients. Both populations were calculated to comprise more than 75% of the expected number of new cases. RESULTS: After a median follow-up of 7 years survival was longer in the prospective population than in the historic one (median 60 versus 39 months; p=0.0002). When comparing only patients eligible for intensive therapy the median survival was 63 versus 44 months (p<0.0001). Attaining a complete response was associated with prolonged event-free survival but not overall survival. The pattern of relapse after transplantation was heterogeneous but could be divided into four major groups; insidious, classical, plasmacytoma form and transformed disease. The median survival after relapse was 29 months. The relapse pattern and time to relapse predicted outcome. Patients relapsing with an insidious or classical form of disease with skeletal events only, or after a long lasting first response were likely to respond well to conventional salvage therapy. In contrast, relapse with multiple symptoms, transformed disease or a short duration of first response implied bad prognosis. INTERPRETATION AND CONCLUSIONS: The relapse pattern after autologous transplantation is heterogeneous and response to salvage therapy is variable. The degree of response and event-free survival after transplantation are not reliable surrogate markers for survival.


This article has been cited by other articles:


Home page
 haematolHome page
H. J.K. van de Velde, X. Liu, G. Chen, A. Cakana, W. Deraedt, and M. Bayssas
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Haematologica, October 1, 2007; 92(10): 1399 - 1406.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.